Cytokines in the systemic inflammatory response syndrome: a review
暂无分享,去创建一个
R. Wade | U Jaffer | R G Wade | T Gourlay | R. Stillman | Usman Jaffer | Terence Gourlay
[1] M. Kretzschmar,et al. Plasma levels of glutathione, alpha-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF alpha on glutathione synthesis. , 1998, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[2] John P. Johnson,et al. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. , 1998, Critical care medicine.
[3] K. Lachapelle,et al. High-dose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients. , 2008, The Annals of thoracic surgery.
[4] M. Kretzschmar,et al. Plasma levels of glutathione, α-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF α on glutathione synthesis , 1998 .
[5] L. Socha,et al. Elevation in interleukin 13 levels in patients diagnosed with systemic inflammatory response syndrome , 2006, Intensive Care Medicine.
[6] I. C. Tudor,et al. The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.
[7] R. Bellomo,et al. Super high flux hemofiltration: a new technique for cytokine removal , 2002, Intensive Care Medicine.
[8] J. A. Kruse,et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.
[9] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[10] Z. Xie,et al. TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. , 1999, The American journal of physiology.
[11] S. Calvano,et al. Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia , 2004, Shock.
[12] V. Pettilä,et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation 1 , 2004, Journal of thrombosis and haemostasis : JTH.
[13] John A Kellum,et al. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-&kgr;B DNA binding, and improves short-term survival in lethal endotoxemia* , 2004, Critical care medicine.
[14] R. Landmann,et al. Function of soluble CD14 in serum from patients with septic shock. , 1996, The Journal of infectious diseases.
[15] J. Kremer,et al. Interleukin-1, -6 and tumor necrosis factor-alpha release is down-regulated in whole blood from septic patients. , 1996, Acta haematologica.
[16] S. Bucklin,et al. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia , 1995, Antimicrobial agents and chemotherapy.
[17] K. Sugimura,et al. Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. , 2002, International journal of molecular medicine.
[18] N. Shapiro,et al. Early goal-directed therapy: a UK perspective , 2006, Emergency Medicine Journal.
[19] H. Werner,et al. Amrinone increases ventricular contractility and diastolic compliance in endotoxemia. , 1995, American journal of respiratory and critical care medicine.
[20] Ning Li,et al. Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response. , 2004, World journal of gastroenterology.
[21] M. Antonelli,et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. , 2009, JAMA.
[22] R. Bone,et al. Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.
[23] J. Platt,et al. The etiology of sepsis: turned inside out. , 2006, Trends in molecular medicine.
[24] G. Nieman,et al. Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. , 2005, The journal of extra-corporeal technology.
[25] P. Scheurich,et al. Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.
[26] W. Feuer,et al. Effects of Treatment with Pentoxifylline on the Cardiovascular Manifestations of Group B Streptococcal Sepsis in the Piglet1 , 1996, Pediatric Research.
[27] C. Ronco,et al. Continuous plasma filtration coupled with sorbents. , 1998, Kidney international. Supplement.
[28] M. Nagaki,et al. Removal of Endotoxin and Cytokines by Adsorbents and the Effect of Plasma Protein Binding , 1991, The International journal of artificial organs.
[29] M. Berger,et al. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome , 2007, Critical care medicine.
[30] J. Peters,et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations , 1997, Intensive Care Medicine.
[31] Steven B. Johnson,et al. Coagulation and complement protein differences between septic and uninfected systemic inflammatory response syndrome patients. , 2007, The Journal of trauma.
[32] J. Schopohl,et al. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. , 1999, Critical care medicine.
[33] I. Young,et al. The effect of lower limb ischaemia-reperfusion on intestinal permeability and the systemic inflammatory response. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[34] D. Kufe,et al. Clinical studies with tumour necrosis factor. , 2007, Ciba Foundation symposium.
[35] A. Lloyd,et al. The in vitro adsorption of cytokines by polymer-pyrolysed carbon. , 2006, Biomaterials.
[36] P. Barie,et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. , 2007, Surgery.
[37] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.
[38] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[39] Gerhard Rakhorst,et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. , 2005, Chest.
[40] M. D. Magdi M.I. Yassin,et al. Lower Limb Ischemia-Reperfusion Injury Triggers a Systemic Inflammatory Response and Multiple Organ Dysfunction , 2001, World Journal of Surgery.
[41] K. Eckardt,et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock* , 2005, Critical care medicine.
[42] S. Ash,et al. Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: a Phase 1 clinical trial. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[43] S. Mikhalovsky. Emerging technologies in extracorporeal treatment: focus on adsorption , 2003, Perfusion.
[44] S. Ash,et al. Cytokines and endotoxin removal by sorbents and its application in push-pull sorbent-based pheresis: the BioLogic-DTPF System. , 1999, Artificial organs.
[45] F. Santolaria,et al. Prognostic value of cytokines in SIRS general medical patients. , 2001, Cytokine.
[46] J. Vincent,et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.
[47] S. Hoerstrup,et al. Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.
[48] J. Christman,et al. Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy , 1998, Intensive Care Medicine.
[49] P. Thompson,et al. Modulatory effects of sCD14 and LBP on LPS-host cell interactions , 2005, Journal of endotoxin research.
[50] Rinaldo Bellomo,et al. The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[51] H. Hirasawa,et al. Cytokine Adsorptive Property of Various Adsorbents in Immunoadsorption Columns and a Newly Developed Adsorbent: An in vitro Study , 2004, Blood Purification.
[52] Incidence of Gram‐negative bacteraemia in sepsis syndrome Implications for immunotherapy , 1994, Anaesthesia.
[53] J. Brock‐Utne. Incidence of Gram‐negative bacteraemia in sepsis syndrome , 1995, Anaesthesia.
[54] M. Zembala,et al. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis , 1996, European Journal of Pediatrics.
[55] M. Langer,et al. The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock , 1995, Intensive Care Medicine.
[56] E. N. Wardle. Bacterial translocation in multiple organ failure: cause or epiphenomenon still unproven. , 1998, The British journal of surgery.
[57] F. Farrokhyar,et al. Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS; SIRS I. , 2006, The Journal of surgical research.
[58] Joel D. Graham,et al. Reducing the Effects of the Systemic Inflammatory Response to Cardiopulmonary Bypass: Can Single Dose Steroids Blunt Systemic Inflammatory Response Syndrome? , 2008, ASAIO journal.
[59] K. Reinhart,et al. Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.
[60] J. Blache,et al. Early postoperative compensatory anti‐inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer , 2002, The British journal of surgery.
[61] N. MacIntyre,et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.
[62] J. Vincent,et al. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. , 1991, Cytokine.